earnings
confidence high
sentiment neutral
materiality 0.55
Enveric Biosciences Q3 net loss narrows to $2.1M; advances EB-003
Enveric Biosciences, Inc.
2024-Q3 EPS
reported -$0.95
vs consensus -$95.47
▲ beat
(+99.0%)
- Net loss of $2.1M ($0.24/share) vs $2.8M ($1.30/share) a year ago; cash $3.1M.
- Lead candidate EB-003 shows oral bioavailability and brain exposure; IND filing expected H2 2025.
- Out-licensed radiation dermatitis product to Aries Science & Technology and EB-002 to MycoMedica.
- Expanded patent estate with five new US patents for EVM301 portfolio.